A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

89bio Clinical Study Site, East Syracuse

89bio Clinical Study Site, Raleigh

89bio Clinical Study Site, Concord

89bio Clinical Study Site, Summerville

89bio Clinical Study Site, Greenwood

89bio Clinical Study Site, Miami Lakes

89bio Clinical Study Site, Sarasota

89bio Clinical Study Site, Ocala

89bio Clinical Study Site, Madison

89bio Clinical Study Site, Hermitage

89bio Clinical Study Site, Lake Charles

89bio Clinical Study Site, Wichita Falls

89bio Clinical Study Site, Houston

89bio Clinical Study Site, San Antonio

89bio Clinical Study Site, San Antonio

89bio Clinical Study Site, Edinburg

89bio Clinical Study Site, Austin

89bio Clinical Study Site, Chandler

89bio Clinical Study Site, Tucson

89bio Clinical Study Site, Montclair

89bio Clinical Study Site, Chula Vista

89bio Clinical Study Site, Huntington Beach

89bio Clinical Study Site, Miami

89bio Clinical Study Site, Berlin

89bio Clinical Study Site, Florham Park

89bio Clinical Study Site, San Juan